Lysoway Therapeutics Announces Phase I Dosing of LW-1017, the First TRPML1 Agonist to Enter Clinical Development

AI Briefing

• – Lysoway Therapeutics announces Phase I dosing of LW-1017, a TRPML1 agonist for neurodegenerative diseases, in clinical trial in Melbourne, Australia.
• – The Phase I study aims to evaluate the safety, tolerability, and pharmacokinetics of LW-1017.
• – The company is developing LW-1017 for Alzheimer's and Parkinson's diseases.